From Startup Avrobio
CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) — AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative lentiviral-based gene therapies to treat rare diseases following a single dose, today announced members of its senior management team are scheduled to present at three upcoming investor conferences.
Wells Fargo Securities 2018 Healthcare ConferenceDate: Wednesday, September 5, 2018Time: 4:10 p.m. ETLocation: The Westin Copley Place Hotel, Boston, MA
Citi’s 13th Annual Biotech ConferenceDate: Thursday, September 6, 2018Time: 10:00 a.m. ETLocation: The Four Seasons, Boston, MA
Morgan Stanley 16th Annual Global Healthcare ConferenceDate: Wednesday, September 12, 2018Time: 8:10 a.m. ETLocation: Grand Hyatt, New York, NY
A live webcast of the presentation of the Morgan Stanley 16th Annual Global Healthcare Conference can be accessed under “Events and Presentations” in the Investors section of the Company’s website at www.avrobio.com.
About AVROBIO, Inc.
AVROBIO, Inc., is a Phase 2 clinical stage gene therapy company focused on developing potentially curative lentiviral-based gene therapies to treat rare diseases following a single dose. AVROBIO’s gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. AVROBIO is focused on the development of its gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit www.avrobio.com.
Katina DortonAVROBIO, Inc.
email@example.comChristopher F. BrinzeyWestwicke Partners
The Yates Network
Source: AVROBIO, Inc.
Please visit their site for more information: Avrobio